These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32053005)

  • 41. Could Killing Bacterial Subpopulations Hit Tuberculosis out of the Park?
    Baranowski C; Rubin EJ
    J Med Chem; 2016 Jul; 59(13):6025-6. PubMed ID: 27322073
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New strategies in fighting TB: targeting Mycobacterium tuberculosis-secreted phosphatases MptpA & MptpB.
    Silva AP; Tabernero L
    Future Med Chem; 2010 Aug; 2(8):1325-37. PubMed ID: 21426021
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis.
    de Steenwinkel JE; de Knegt GJ; ten Kate MT; van Belkum A; Verbrugh HA; Kremer K; van Soolingen D; Bakker-Woudenberg IA
    J Antimicrob Chemother; 2010 Dec; 65(12):2582-9. PubMed ID: 20947621
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In silico discovery and virtual screening of multi-target inhibitors for proteins in Mycobacterium tuberculosis.
    Speck-Planche A; Kleandrova VV; Luan F; Cordeiro MN
    Comb Chem High Throughput Screen; 2012 Sep; 15(8):666-73. PubMed ID: 22452349
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diphenylether-Modified 1,2-Diamines with Improved Drug Properties for Development against Mycobacterium tuberculosis.
    Foss MH; Pou S; Davidson PM; Dunaj JL; Winter RW; Pou S; Licon MH; Doh JK; Li Y; Kelly JX; Dodean RA; Koop DR; Riscoe MK; Purdy GE
    ACS Infect Dis; 2016 Jul; 2(7):500-8. PubMed ID: 27626102
    [TBL] [Abstract][Full Text] [Related]  

  • 46. More than cholesterol catabolism: regulatory vulnerabilities in Mycobacterium tuberculosis.
    Bonds AC; Sampson NS
    Curr Opin Chem Biol; 2018 Jun; 44():39-46. PubMed ID: 29906645
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of novel acetohydroxyacid synthase inhibitors as active agents against Mycobacterium tuberculosis by virtual screening and bioassay.
    Wang D; Zhu X; Cui C; Dong M; Jiang H; Li Z; Liu Z; Zhu W; Wang JG
    J Chem Inf Model; 2013 Feb; 53(2):343-53. PubMed ID: 23316686
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Trends in discovery of new drugs for tuberculosis therapy.
    Riccardi G; Pasca MR
    J Antibiot (Tokyo); 2014 Sep; 67(9):655-9. PubMed ID: 25095807
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthetic calanolides with bactericidal activity against replicating and nonreplicating Mycobacterium tuberculosis.
    Zheng P; Somersan-Karakaya S; Lu S; Roberts J; Pingle M; Warrier T; Little D; Guo X; Brickner SJ; Nathan CF; Gold B; Liu G
    J Med Chem; 2014 May; 57(9):3755-72. PubMed ID: 24694175
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.
    Chikhale RV; Barmade MA; Murumkar PR; Yadav MR
    J Med Chem; 2018 Oct; 61(19):8563-8593. PubMed ID: 29851474
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent advances for identification of new scaffolds and drug targets for Mycobacterium tuberculosis.
    Dhiman R; Singh R
    IUBMB Life; 2018 Sep; 70(9):905-916. PubMed ID: 29761628
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Replication rates of Mycobacterium tuberculosis in human macrophages do not correlate with mycobacterial antibiotic susceptibility.
    Raffetseder J; Pienaar E; Blomgran R; Eklund D; Patcha Brodin V; Andersson H; Welin A; Lerm M
    PLoS One; 2014; 9(11):e112426. PubMed ID: 25386849
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection.
    Marimani M; Ahmad A; Duse A
    Tuberculosis (Edinb); 2018 Dec; 113():200-214. PubMed ID: 30514504
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chemical disarming of isoniazid resistance in
    Flentie K; Harrison GA; Tükenmez H; Livny J; Good JAD; Sarkar S; Zhu DX; Kinsella RL; Weiss LA; Solomon SD; Schene ME; Hansen MR; Cairns AG; Kulén M; Wixe T; Lindgren AEG; Chorell E; Bengtsson C; Krishnan KS; Hultgren SJ; Larsson C; Almqvist F; Stallings CL
    Proc Natl Acad Sci U S A; 2019 May; 116(21):10510-10517. PubMed ID: 31061116
    [No Abstract]   [Full Text] [Related]  

  • 55. 6-hydrogen-8-methylquinolones active against replicating and non-replicating Mycobacterium tuberculosis.
    Tabarrini O; Sabatini S; Massari S; Pieroni M; Franzblau SG; Cecchetti V
    Chem Biol Drug Des; 2012 Nov; 80(5):781-6. PubMed ID: 22889240
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Development of new anti-tuberculosis drugs: the strategy of unconventional microbial culture and silencing gene activation].
    Teng T; Xie L; Xie J
    Sheng Wu Gong Cheng Xue Bao; 2018 Aug; 34(8):1306-1315. PubMed ID: 30152216
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of novel inhibitors of nonreplicating Mycobacterium tuberculosis using a carbon starvation model.
    Grant SS; Kawate T; Nag PP; Silvis MR; Gordon K; Stanley SA; Kazyanskaya E; Nietupski R; Golas A; Fitzgerald M; Cho S; Franzblau SG; Hung DT
    ACS Chem Biol; 2013 Oct; 8(10):2224-34. PubMed ID: 23898841
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mycobacterium tuberculosis-Secreted Tyrosine Phosphatases as Targets Against Tuberculosis: Exploring Natural Sources in Searching for New Drugs.
    Mascarello A; Chiaradia-Delatorre LD; Mori M; Terenzi H; Botta B
    Curr Pharm Des; 2016; 22(12):1561-9. PubMed ID: 26759082
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Validation of Mycobacterium tuberculosis dihydroneopterin aldolase as a molecular target for anti-tuberculosis drug development.
    Falcão VC; Villela AD; Rodrigues-Junior VS; Pissinate K; Eichler P; Pinto AF; Basso LA; Santos DS; Bizarro CV
    Biochem Biophys Res Commun; 2017 Apr; 485(4):814-819. PubMed ID: 28257847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.